Kathryn Stephenson

French-Austrian drugmaker Valneva's vaccine candidate against chikungunya, a mosquito-borne virus that causes occasional outbreaks across the world, showed promising results in a large new trial, a study said on Tuesday.

French-Austrian drugmaker Valneva's vaccine candidate against chikungunya, a mosquito-borne virus that causes occasional outbreaks across the world, showed promising results in a large new trial, a study said on Tuesday.